These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27218790)

  • 21. Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.
    Hansson J; Bartley K; Karagiannis T; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Yim YM; Dimier N; Fittipaldo A; Basset-Séguin N; Hauschild A
    Eur J Dermatol; 2018 Dec; 28(6):775-783. PubMed ID: 30698147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
    Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
    Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma.
    Barker CA; Dufault S; Arron ST; Ho AL; Algazi AP; Dunn LA; Humphries AA; Hultman C; Lian M; Knott PD; Yom SS
    J Clin Oncol; 2024 Jul; 42(19):2327-2335. PubMed ID: 38630954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
    Keserü M; Green S; Dulz S
    Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
    [No Abstract]   [Full Text] [Related]  

  • 25. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
    Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
    Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
    Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
    J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
    Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
    Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma.
    González AR; Etchichury D; Gil ME; Del Aguila R
    Ophthalmic Plast Reconstr Surg; 2019; 35(1):56-61. PubMed ID: 30444747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma.
    Curragh DS; Huilgol SC; Selva D
    Eye (Lond); 2021 Oct; 35(10):2740-2745. PubMed ID: 33235336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vismodegib: in locally advanced or metastatic basal cell carcinoma.
    Keating GM
    Drugs; 2012 Jul; 72(11):1535-41. PubMed ID: 22788238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
    Meani RE; Lim SW; Chang AL; Kelly JW
    Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
    Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib.
    Castillo JM; Knol AC; Nguyen JM; Khammari A; Saint-Jean M; Dreno B
    Eur J Dermatol; 2016 Oct; 26(5):452-459. PubMed ID: 27346829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities.
    Spallone G; Sollena P; Ventura A; Fargnoli MC; Gutierrez C; Piccerillo A; Tambone S; Bianchi L; Peris K
    Dermatol Ther; 2019 Nov; 32(6):e13108. PubMed ID: 31606940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.
    Yin VT; Pfeiffer ML; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2013; 29(2):87-92. PubMed ID: 23446297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.
    Calzavara Pinton P; Licitra L; Peris K; Santoro A; Ascierto PA
    Future Oncol; 2015; 11(9):1429-35. PubMed ID: 25952787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
    Sekulic A; Yoo S; Kudchadkar R; Guillen J; Rogers G; Chang ALS; Guenthner S; Raskin B; Dawson K; Mun Y; Chu L; McKenna E; Lacouture M
    PLoS One; 2022; 17(1):e0262151. PubMed ID: 35030185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
    Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
    J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.